Bioprinting-Enabled Biomaterials: A Cutting-Edge Strategy for Future Osteoarthritis Therapy

Xinquan Yang,Peilong Liu,Yan Zhang,Jun Lu,Hongmou Zhao
DOI: https://doi.org/10.2147/ijn.s432468
IF: 7.033
2023-11-02
International Journal of Nanomedicine
Abstract:Xinquan Yang, &ast Peilong Liu, &ast Yan Zhang, Jun Lu, Hongmou Zhao Department of Foot and Ankle Surgery, Honghui Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710054, People's Republic of China &astThese authors contributed equally to this work Correspondence: Hongmou Zhao, Department of Foot and Ankle Surgery, Honghui Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710054, People's Republic of China, Email Bioprinting is an advanced technology that allows for the precise placement of cells and biomaterials in a controlled manner, making significant contributions in regenerative medicine. Notably, bioprinting-enabled biomaterials have found extensive application as drug delivery systems (DDS) in the treatment of osteoarthritis (OA). Despite the widespread utilization of these biomaterials, there has been limited comprehensive research summarizing the recent advances in this area. Therefore, this review aims to explore the noteworthy developments and challenges associated with utilizing bioprinting-enabled biomaterials as effective DDS for the treatment of OA. To begin, we provide an overview of the complex pathophysiology of OA, highlighting the shortcomings of current treatment modalities. Following this, we conduct a detailed examination of various bioprinting technologies and discuss the wide range of biomaterials employed in DDS applications for OA therapy. Finally, by placing emphasis on their transformative potential, we discuss the incorporation of crucial cellular components such as chondrocytes and mesenchymal stem cells into bioprinted constructs, which play a pivotal role in promoting tissue regeneration and repair. Keywords: drug delivery, bioprinting, osteoarthritis, biomaterials, translation Graphical Osteoarthritis (OA) is a chronic joint disease that primarily affects the elderly, often leading to disability and a substantial decline in their quality of life during their later years. 1 The existing treatment modalities for OA have marked limitations, including their primarily symptomatic relief, systemic side effects, limited disease-modifying capabilities, invasive procedures, lack of personalization, temporary relief, and sometimes prohibitive costs. Moreover, OA treatment options face challenges in promoting effective tissue regeneration due to the limited regenerative capacity of damaged joint tissues. In this context, bioprinting-enabled drug delivery systems (DDS) offer a promising alternative, with the potential to provide precise, localized drug delivery, sustained release, tissue regeneration support, and personalized treatment options, addressing many of these limitations and improving the overall management of OA. 2 Unlike conventional treatment options, which are often limited in their efficacy, bioprinting-enabled biomaterials offer a transformative avenue for combating OA. 3 This innovative technology allows for the fabrication of intricate 3D structures that closely mimic the complexity of native tissues. With precision and finesse, bioprinting enables the controlled deposition of cells and biomaterials, resulting in the construction of structures that bear an eminent resemblance to the natural tissue microenvironment. 4 By replicating the intricate architecture of the affected joint, bioprinting holds the potential to support the regeneration of damaged tissue and even impede the relentless progression of the disease. One of the most critical aspects of bioprinting is the ability to design treatment to the specific needs of individual patients. 5 The ability of customizing bioprinting-enabled biomaterials according to the individual's personal characteristics, provides a paradigm shift in treatment outcomes. By considering factors such as the patient's physiology, severity of the condition, and other individual characteristics, bioprinting paves the way for personalized interventions that yield improved outcomes. 6 Furthermore, bioprinting technology offers a multitude of advantages that transcend the limitations of traditional therapies. By reducing the necessity for invasive procedures, which are often accompanied by risks and complications, bioprinting offers a safer and less intrusive route to recovery. 7 OA primarily affects specific joints, and its chronic nature necessitates long-term therapy. Bioprinting offers precise drug placement directly into the affected joint space, reducing systemic exposure and minimizing systemic side effects. 8 Furthermore, bioprinted constructs can control drug release kinetics, providing sustained therapeutic agents over an extended period, aligning with the chronicity of OA. Moreover, OA is characterized by the progressive loss of articular cartilage, inflammation, and tiss -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology
What problem does this paper attempt to address?